Top

Published in:

01-11-2012 | Original article

The effect of angiotensin-converting enzyme inhibitor use on bone loss in elderly Chinese

Authors: Ya-feng Zhang, Ling Qin, Ping-chung Leung, Timothy C. Y. Kwok

Published in: Journal of Bone and Mineral Metabolism | Issue 6/2012

Abstract

In this study we analyzed the independent effect of angiotensin-converting enzyme (ACE) inhibitor use on bone loss in elderly Chinese. The subjects were from two cohort studies which investigated the risk factors of osteoporotic fractures in Hong Kong-dwelling elderly Chinese. A total of 2161 subjects (1280 male, 881 female) were selected for this analysis. The results showed that unadjusted annualized percentage bone loss of male ACE inhibitor users was not different from non-users; however, female ACE inhibitor users had significantly greater bone loss both in total hip and femoral neck than non-users. After adjusting for significant confounders, female continuous ACE inhibitor users had significantly greater bone loss at total hip and femoral neck. In conclusion, continuous use of ACE inhibitors over 4 years was associated with increased bone loss in total hip and femoral neck in older Chinese women.

Rosamond W, Flegal K, Furie K, Go A, Greenlund K et al (2008) Heart disease and stroke statistics–2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117:e25–146PubMedCrossRef

Cole ZA, Dennison EM, Cooper C (2008) Osteoporosis epidemiology update. Curr Rheumatol Rep 10:92–96PubMedCrossRef

Vestergaard P, Rejnmark L, Mosekilde L (2009) Hypertension is a risk factor for fractures. Calcif Tissue Int 84:103–111PubMedCrossRef

Peach MJ (1977) Renin-angiotensin system: biochemistry and mechanisms of action. Physiol Rev 57:313–370PubMed

Rejnmark L, Vestergaard P, Mosekilde L (2006) Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens 24:581–589PubMedCrossRef

Reid IR, Gamble GD, Grey AB, Black DM, Ensrud KE, Browner WS, Bauer DC (2005) Beta-blocker use, BMD, and fractures in the study of osteoporotic fractures. J Bone Miner Res 20:613–618PubMedCrossRef

Liu YY, Yao WM, Wu T, Xu BL, Chen F, Cui L (2011) Captopril improves osteopenia in ovariectomized rats and promotes bone formation in osteoblasts. J Bone Miner Metab 29:149–158PubMedCrossRef

Schlienger RG, Kraenzlin ME, Jick SS, Meier CR (2004) Use of beta-blockers and risk of fractures. JAMA 292:1326–1332PubMedCrossRef

Pérez-Castrillón JL, Silva J, Justo I, Sanz A, Martín-Luquero M, Igea R, Escudero P, Pueyo C, Díaz C, Hernández G, Dueñas A (2003) Effect of quinapril, quinapril-hydrochlorothiazide, and enalapril on the bone mass of hypertensive subjects: relationship with angiotensin converting enzyme polymorphisms. Am J Hypertens 16:453–459PubMedCrossRef

10.

Lynn H, Kwok T, Wong SY, Woo J, Leung PC (2006) Angiotensin converting enzyme inhibitor use is associated with higher bone mineral density in elderly Chinese. Bone 38:584–588PubMedCrossRef

11.

Masunari N, Fujiwara S, Nakata Y, Furukawa K, Kasagi F (2008) Effect of angiotensin converting enzyme inhibitor and benzodiazepine intake on bone loss in older Japanese. Hiroshima J Med Sci 57:17–25PubMed

12.

Lau EM, Leung PC, Kwok T, Woo J, Lynn H, Orwoll E, Cummings S, Cauley J (2006) The determinants of bone mineral density in Chinese men–results from Mr. Os (Hong Kong), the first cohort study on osteoporosis in Asian men. Osteoporos Int 17:297–303PubMedCrossRef

13.

Kwok T, Leung J, Zhang YF, Bauer D, Ensrud KE, Barrett-Connor E, Leung PC, Osteoporotic Fractures in Men (MrOS) Research Group (2011) Does the use of ACE inhibitors or angiotensin receptor blockers affect bone loss in older men? Osteoporos Int Nov 12 [Epub ahead of print]

14.

Inzerillo AM, Epstein S (2004) Osteoporosis and diabetes mellitus. Rev Endocr Metab Disord 5:261–268PubMedCrossRef

15.

Gerdhem P, Isaksson A, Akesson K, Obrant KJ (2005) Increased bone density and decreased bone turnover, but no evident alteration of fracture susceptibility in elderly women with diabetes mellitus. Osteoporos Int 16:1506–1512PubMedCrossRef

16.

Dvorak MM, De Joussineau C, Carter DH, Pisitkun T, Knepper MA, Gamba G, Kemp PJ, Riccardi D (2007) Thiazide diuretics directly induce osteoblast differentiation and mineralized nodule formation by interacting with a sodium chloride co-transporter in bone. J Am Soc Nephrol 18:2509–2516PubMedCrossRef

17.

Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P, Sambrook PN, HORIZON investigators (2009) Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373:1253–1263PubMedCrossRef

18.

Hatton R, Stimpel M, Chambers TJ (1997) Angiotensin II is generated from angiotensin I by bone cells and stimulates osteoclastic bone resorption in vitro. J Endocrinol 152:5–10PubMedCrossRef

19.

Shimizu H, Nakagami H, Osako MK, Hanayama R, Kunugiza Y, Kizawa T, Tomita T, Yoshikawa H, Ogihara T, Morishita R (2008) Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J 22:2465–2475PubMedCrossRef

20.

Skeggs LT Jr, Kahn JR, Lentz K, Shumway NP (1957) The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med 106:439–453PubMedCrossRef

21.

Erdös EG (1990) Angiotensin I converting enzyme and the changes in our concepts through the years. Lewis K. Dahl memorial lecture. Hypertension 16:363–370PubMedCrossRef

22.

Lerner UH, Jones IL, Gustafson GT (1987) Bradykinin, a new potential mediator of inflammation-induced bone resorption. Studies of the effects on mouse calvarial bones and articular cartilage in vitro. Arthritis Rheum 30:530–540PubMedCrossRef

23.

Lerner UH (1991) Bradykinin synergistically potentiates interleukin-1 induced bone resorption and prostanoid biosynthesis in neonatal mouse calvarial bones. Biochem Biophys Res Commun 175:775–783PubMedCrossRef

24.

Pitt B (1995) “Escape” of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther 9:145–149PubMedCrossRef

25.

López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, Tendera M, Waagstein F, Kjekshus J, Lechat P, Torp-Pedersen C (2004) Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J 25:1454–1470PubMedCrossRef

26.

Koshida H, Takeda R, Miyamori I (1998) Lisinopril decreases plasma free testosterone in male hypertensive patients and increases sex hormone binding globulin in female hypertensive patients. Hypertens Res 21:279–282PubMedCrossRef

27.

Kwok T, Ohlsson C, Vandenput L, Tang N, Zhang YF, Tomlinson B, Leung PC (2010) ACE inhibitor use was associated with lower serum dehydroepiandrosterone concentrations in older men. Clin Chim Acta 411:1122–1125PubMedCrossRef

28.

Ma YF, Stimpel M, Liang H, Pun S, Jee WS (1997) Impact of antihypertensive therapy on the skeleton: effects of moexipril and hydrochlorothiazide on osteopenia in spontaneously hypertensive ovariectomized rats. J Endocrinol 154:467–474PubMedCrossRef

Title: The effect of angiotensin-converting enzyme inhibitor use on bone loss in elderly Chinese
Authors: Ya-feng Zhang
Ling Qin
Ping-chung Leung
Timothy C. Y. Kwok
Publication date: 01-11-2012
Publisher: Springer Japan
Published in: Journal of Bone and Mineral Metabolism / Issue 6/2012
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI: https://doi.org/10.1007/s00774-012-0363-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2012

The distribution of FRAX®-based probabilities in women from Japan

Adult hypophosphatasia with painful periarticular calcification treated with surgical resection

LIST OF REVIEWERS 2011–2012

Runx-2 gene expression is associated with age-related changes of bone mineral density in the healthy young-adult population

Osteoconductive action of alendronate after implantation of beta tricalcium phosphate in rat adjuvant-induced arthritis

The skeletal effects of thiazolidinedione and metformin on insulin-resistant mice

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials